{
    "data": [
        {
            "id": "6432fc0457b1c7a31500001f_0001",
            "question": "Which gene is most frequently mutated in hereditary angioedema ?",
            "type": "factoid",
            "context": "Almost all cases of HAE are caused by mutations in the SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1 esterase inhibitor), a serine protease inhibitor that normally inhibits proteases in the contact, complement, and fibrinolytic systems"
        },
        {
            "id": "641d8fd6690f196b51000041_0001",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "multiple sclerosis, aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder, and MOG-immunoglobulin G-associated disorde"
        },
        {
            "id": "641d8fd6690f196b51000041_0002",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": " The antibody against aquaporin-4 (aquaporin-4)-immunoglobulin G (immunoglobulin G) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker for neuromyelitis optica spectrum disorders"
        },
        {
            "id": "641d8fd6690f196b51000041_0003",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity."
        },
        {
            "id": "641d8fd6690f196b51000041_0004",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "glial fibrillary acidic protein might be the most appropriate for monitoring Neuromyelitis Optica Spectrum Disorders longitudinally, which warrants future confirming studies."
        },
        {
            "id": "641d8fd6690f196b51000041_0005",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "We prospectively recruited consecutive Neuromyelitis Optica Spectrum Disorders patients with anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12\u2009months of follow-up (main period), and at attacks. "
        },
        {
            "id": "641d8fd6690f196b51000041_0006",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "During the study, five (8%) patients developed new attacks; only serum glial fibrillary acidic protein levels increased consistently upon these events compared with baseline levels."
        },
        {
            "id": "641d8fd6690f196b51000041_0007",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "Neuromyelitis optica (Neuromyelitis optica) is an inflammatory disease that resembles MS in the relapsing clinical course of optic neuritis and myelitis. Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (aquaporin-4)\u00a0are detected in the core group of patients"
        },
        {
            "id": "641d8fd6690f196b51000041_0008",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "During the acute phase of Neuromyelitis Optica Spectrum Disorders and MOGAD, plasma C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the Neuromyelitis Optica Spectrum Disorders BBB damage."
        },
        {
            "id": "641d8fd6690f196b51000041_0009",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": "The discovery of the pathogenic aquaporin-4 (aquaporin-4)-immunoglobulin G autoantibody and characterization of Neuromyelitis Optica Spectrum Disorders as an autoimmune astrocytopathy have spearheaded the identification of key immunologic therapeutic targets in this disease, including but not limited to the complement system, the interleukin 6 (interleukin 6) receptor, and B cells. "
        },
        {
            "id": "641d8fd6690f196b51000041_0010",
            "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (Neuromyelitis Optica Spectrum Disorders) to monitor disease activity?",
            "type": "list",
            "context": ". As our understanding regarding the immune pathophysiology of Neuromyelitis Optica Spectrum Disorders expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (glial fibrillary acidic protein), may facilitate earlier relapse detection and inform long-term treatment decisions."
        },
        {
            "id": "6429d5c557b1c7a315000006_0001",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Due to several inflammatory changes that occur in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors, platelet activation leads to thrombus formation in coronary and cerebral vessels, leading to myocardial infarction and cerebrovascular accidents, respectively."
        },
        {
            "id": "6429d5c557b1c7a315000006_0002",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "A prothrombotic state is reported with severe Coronavirus Disease 2019 infection, which can manifest in venous and arterial thrombotic events."
        },
        {
            "id": "6429d5c557b1c7a315000006_0003",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": " In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis reported in 16.1% and pulmonary embolism in 12.6% of patients, despite anticoagulant thromboprophylaxis, and were associated with high mortality."
        },
        {
            "id": "6429d5c557b1c7a315000006_0004",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Despite thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with Coronavirus Disease 2019 on the ICU."
        },
        {
            "id": "6429d5c557b1c7a315000006_0005",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Emerging evidence points to an association between severe clinical presentation of Coronavirus Disease 2019 and increased risk of thromboembolism. One-third of patients hospitalized due to severe Coronavirus Disease 2019 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke."
        },
        {
            "id": "6429d5c557b1c7a315000006_0006",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (disseminated intravascular coagulation) rates, but data are limited."
        },
        {
            "id": "6429d5c557b1c7a315000006_0007",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "The radiographically confirmed VTE rate was 4.8% (95% confidence interval [confidence interval], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% confidence interval, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% confidence interval, 2.9-7.3) and 2.3% (95% confidence interval, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% confidence interval, 3.9-13.3) and 5.6% (95% confidence interval, 2.4-10.7), respectively."
        },
        {
            "id": "6429d5c557b1c7a315000006_0008",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%)."
        },
        {
            "id": "6429d5c557b1c7a315000006_0009",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "No patient developed disseminated intravascular coagulation."
        },
        {
            "id": "6429d5c557b1c7a315000006_0010",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Despite anticoagulation, a high number of patients with ARDS secondary to Coronavirus Disease 2019 developed life-threatening thrombotic complications."
        },
        {
            "id": "6429d5c557b1c7a315000006_0011",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Critically ill COVID patients are at increased risk of serious thrombotic events and hence increased mortality. On the other side, Coronavirus Disease 2019 patients are also showing major life-threatening bleeds, especially when systemic anticoagulation is used."
        },
        {
            "id": "6429d5c557b1c7a315000006_0012",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed, two required embolization for bleeding control and one died from hemorrhagic shock."
        },
        {
            "id": "6429d5c557b1c7a315000006_0013",
            "question": "What are the major thrombotic complications in patients with Coronavirus Disease 2019?",
            "type": "list",
            "context": "Our analysis does not suggest that rates of intracerebral hemorrhage are higher in patients with Coronavirus Disease 2019. The higher mortality in patients with intracerebral hemorrhage and Coronavirus Disease 2019 compared with those without Coronavirus Disease 2019 is likely mediated by higher frequency of comorbidities and adverse in-hospital events."
        },
        {
            "id": "63f03c47f36125a42600001e_0001",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based Coronavirus Disease 2019 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial."
        },
        {
            "id": "63f03c47f36125a42600001e_0002",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (Coronavirus Disease 2019) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based Coronavirus Disease 2019 vaccine (ZF2001, hereafter referred to as ZF)."
        },
        {
            "id": "63f03c47f36125a42600001e_0003",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "CONCLUSIONS: Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. "
        },
        {
            "id": "63f03c47f36125a42600001e_0004",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "Conclusion: SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. "
        },
        {
            "id": "63f03c47f36125a42600001e_0005",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice."
        },
        {
            "id": "63f03c47f36125a42600001e_0006",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study. "
        },
        {
            "id": "63f03c47f36125a42600001e_0007",
            "question": "ZF2001 is used for which disease?",
            "type": "factoid",
            "context": "Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (receptor-binding domain) of prototype SARS-CoV-2. "
        },
        {
            "id": "642c82c557b1c7a315000012_0001",
            "question": "What mammal has the lowest known chromosome number?",
            "type": "factoid",
            "context": "Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\u00a0= 6),"
        },
        {
            "id": "642c82c557b1c7a315000012_0002",
            "question": "What mammal has the lowest known chromosome number?",
            "type": "factoid",
            "context": "Indian Muntjac, a Placental Mammal with Only Three Chromosomes."
        },
        {
            "id": "642c82c557b1c7a315000012_0003",
            "question": "What mammal has the lowest known chromosome number?",
            "type": "factoid",
            "context": " Indian muntjac, a placental mammal with the lowest known chromosome number (n\u00a0=\u00a03)."
        },
        {
            "id": "6429b41757b1c7a315000004_0001",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Histone lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation. The combinatorial action of these modifications regulates critical DNA processes including replication, repair, and transcription. In addition, enzymes that modify histone lysine and arginine residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders."
        },
        {
            "id": "6429b41757b1c7a315000004_0002",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Histone methylation represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms."
        },
        {
            "id": "6429b41757b1c7a315000004_0003",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Studies into posttranslational modifications of histones, notably acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression."
        },
        {
            "id": "6429b41757b1c7a315000004_0004",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Microsequence analyses of H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4 is a highly conserved site of methylation, which to date, is the major site detected in Tetrahymena and yeast."
        },
        {
            "id": "6429b41757b1c7a315000004_0005",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena."
        },
        {
            "id": "6429b41757b1c7a315000004_0006",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Chromatin remodelling events play an important role in the secondary metabolism of filamentous fungi. Previously, we showed that a bacterium, Streptomyces rapamycinicus, is able to reprogram the histone-modifying Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA) complex of the model fungus Aspergillus nidulans. Consequently, the histone H3 amino acids lysine 9 and lysine 14 at distinct secondary metabolism genes were specifically acetylated during the bacterial fungal interaction, which, furthermore, was associated with the activation of the otherwise silent orsellinic acid gene cluster."
        },
        {
            "id": "6429b41757b1c7a315000004_0007",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Over the past year or so, methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression, promoter regulation and the propagation of a repressed state via DNA methylation."
        },
        {
            "id": "6429b41757b1c7a315000004_0008",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation, acetylation, and methylation, which have profound effects on the remodeling of chromatin."
        },
        {
            "id": "6429b41757b1c7a315000004_0009",
            "question": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
            "type": "list",
            "context": "Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin. Concomitantly, several families of histone methyltransferases (HMTs) have been identified that catalyze the methylation of specific arginines or lysines in histones H3 and H4."
        },
        {
            "id": "643305b257b1c7a315000025_0001",
            "question": "Which company produces Ruconest?",
            "type": "factoid",
            "context": "Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency."
        },
        {
            "id": "641635fa690f196b5100001c_0001",
            "question": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
            "type": "factoid",
            "context": "The mean [median] ages in years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (creatine kinase), 4.6 [4.6]; DNA/muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1.4]."
        },
        {
            "id": "641635fa690f196b5100001c_0002",
            "question": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
            "type": "factoid",
            "context": "The mean age of diagnosis was 4.43\u2009years. "
        },
        {
            "id": "641635fa690f196b5100001c_0003",
            "question": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
            "type": "factoid",
            "context": " The mean age for DMD diagnosis was 4.9 years. "
        },
        {
            "id": "641635fa690f196b5100001c_0004",
            "question": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
            "type": "factoid",
            "context": "In 10 cases of the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age."
        },
        {
            "id": "6422e7f0690f196b51000045_0001",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Hepcidin, a key regulator of iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia."
        },
        {
            "id": "6422e7f0690f196b51000045_0002",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis."
        },
        {
            "id": "6422e7f0690f196b51000045_0003",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Recent data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism"
        },
        {
            "id": "6422e7f0690f196b51000045_0004",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "The regulation of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron demand, making use of a range of regulatory mechanisms that center on the bone morphogenetic protein signaling pathway. "
        },
        {
            "id": "6422e7f0690f196b51000045_0005",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "In mammalian systems, iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin receptor as well as the sole known cellular exporter of iron. "
        },
        {
            "id": "6422e7f0690f196b51000045_0006",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "y reducing iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary iron."
        },
        {
            "id": "6422e7f0690f196b51000045_0007",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Information on the metabolism of hepcidin and its possible significance as a biochemical parameter in iron deficiency anemia is reported in this review, which was based on a survey of the databases PubMed and LILACS for articles published between 2006 and 2010 on hepcidin as a biomarker for the regulation of iron metabolism"
        },
        {
            "id": "6422e7f0690f196b51000045_0008",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Hepcidin is related to the pathogenesis of chronic renal failure anemia, which is considered a chronic inflammatory state"
        },
        {
            "id": "6422e7f0690f196b51000045_0009",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "Iron transport across the human placenta is regulated by hepcidin."
        },
        {
            "id": "6422e7f0690f196b51000045_0010",
            "question": "Hepcidin is a key regulator of what processes?",
            "type": "list",
            "context": "we investigate the role of hepcidin, a master regulator of iron homeostasis, on regulation of iron transport across trophoblast cells."
        },
        {
            "id": "6433050157b1c7a315000024_0001",
            "question": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
            "type": "factoid",
            "context": "Conestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)."
        },
        {
            "id": "6417900b690f196b5100002a_0001",
            "question": "What type of DMD can viltolarsen be used for?",
            "type": "factoid",
            "context": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (phosphorodiamidate morpholino antisense oligonucleotide) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD)"
        },
        {
            "id": "6417900b690f196b5100002a_0002",
            "question": "What type of DMD can viltolarsen be used for?",
            "type": "factoid",
            "context": "Viltolarsen restores the reading frame of the DMD gene by skipping \u00a0exon 53\u00a0and produces a truncated but functional form of dystrophin."
        },
        {
            "id": "63f57ea133942b094c000005_0001",
            "question": "What is the triad of the Cat eye syndrome?",
            "type": "list",
            "context": "Cat-eye syndrome is a rare genetic disease that involves the proximal long (q) arm of chromosome 22. The classic clinical triad includes coloboma of the iris, ears, and anal malformations. "
        },
        {
            "id": "63f57ea133942b094c000005_0002",
            "question": "What is the triad of the Cat eye syndrome?",
            "type": "list",
            "context": "BACKGROUND: Cat eye syndrome (Cat eye syndrome) is a rare chromosomal disease, with estimated incidence of about 1 in 100,000 live newborns. The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients, and other congenital defects may also be observed. "
        },
        {
            "id": "64178fea690f196b51000028_0001",
            "question": "What types of DMD can eteplirsen be used for?",
            "type": "factoid",
            "context": "treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations."
        },
        {
            "id": "64178fea690f196b51000028_0002",
            "question": "What types of DMD can eteplirsen be used for?",
            "type": "factoid",
            "context": "A relationship between exon skipping and dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51\u00ae) "
        },
        {
            "id": "6426d131690f196b5100004e_0001",
            "question": "In what organ would you find the Ashwell receptor?",
            "type": "factoid",
            "context": "From these data, we inferred an additional hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-terminated glycoproteins. "
        },
        {
            "id": "6426d131690f196b5100004e_0002",
            "question": "In what organ would you find the Ashwell receptor?",
            "type": "factoid",
            "context": " This study was designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte."
        },
        {
            "id": "6426d131690f196b5100004e_0003",
            "question": "In what organ would you find the Ashwell receptor?",
            "type": "factoid",
            "context": "The asialoglycoprotein receptor (asialoglycoprotein receptor) is a hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood in health and disease. T"
        },
        {
            "id": "6426d131690f196b5100004e_0004",
            "question": "In what organ would you find the Ashwell receptor?",
            "type": "factoid",
            "context": "The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine"
        },
        {
            "id": "6429e17657b1c7a315000007_0001",
            "question": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
            "type": "list",
            "context": "Furthermore, 218 p53-bound enhancers (Enhp53) were identified by analyzing p53 ChIP-seq in HepG2 cells after DNA damage. The results showed that the enhancer expression and histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53 participated in regulating enhancer activity and chromatin structure."
        },
        {
            "id": "6429e17657b1c7a315000007_0002",
            "question": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
            "type": "list",
            "context": "In general, transcription start sites of actively transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K27ac."
        },
        {
            "id": "6429e17657b1c7a315000007_0003",
            "question": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
            "type": "list",
            "context": "DNA methylation at promoters is largely correlated with inhibition of gene expression. However, the role of DNA methylation at enhancers is not fully understood, although a crosstalk with chromatin marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4me1, a chromatin hallmark of enhancers."
        },
        {
            "id": "6429e17657b1c7a315000007_0004",
            "question": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
            "type": "list",
            "context": "We hypothesized \"seesaw\" dynamics between H3K4me1 and H3K4me3 in the low and intermediate DNA methylation range, in which DNA methylation discriminates between enhancers and promoters, marked by H3K4me1 and H3K4me3, respectively. Low methylated regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active enhancers, and decreases linearly in the higher range of the intermediate DNA methylation. Thus, the decrease of the DNA methylation switches smoothly the state of the enhancers from a primed to an active state."
        },
        {
            "id": "64178ffb690f196b51000029_0001",
            "question": "What type of DMD can casimersen be used for?",
            "type": "factoid",
            "context": "Casimersen received its first approval on 25\u00a0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\u00a045 skipping."
        },
        {
            "id": "63eeefc5f36125a426000009_0001",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "BACKGROUND: CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in a phase 1 clinical trial. "
        },
        {
            "id": "63eeefc5f36125a426000009_0002",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "METHODS: We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season."
        },
        {
            "id": "63eeefc5f36125a426000009_0003",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "CONCLUSIONS: CIS43LS was protective against P. falciparum infection over a 6-month malaria season in Mali without evident safety concerns. "
        },
        {
            "id": "63eeefc5f36125a426000009_0004",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria prevention."
        },
        {
            "id": "63eeefc5f36125a426000009_0005",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. "
        },
        {
            "id": "63eeefc5f36125a426000009_0006",
            "question": "What is targeted by CIS43LS?",
            "type": "factoid",
            "context": "CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection."
        },
        {
            "id": "64172bb2690f196b5100001e_0001",
            "question": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
            "type": "factoid",
            "context": "RNA polymerases initiate transcription at DNA sequences called promoters."
        },
        {
            "id": "64172bb2690f196b5100001e_0002",
            "question": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
            "type": "factoid",
            "context": "Polymerases are integral factors of gene expression and are essential for the maintenance and transmission of genetic information. RNA polymerases (RNA polymerases) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase."
        },
        {
            "id": "64172bb2690f196b5100001e_0003",
            "question": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
            "type": "factoid",
            "context": "conventional transcription factors trigger transcription by the RNA polymerase II (polymerase II) paused within the proximal promoter region."
        },
        {
            "id": "64172bb2690f196b5100001e_0004",
            "question": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
            "type": "factoid",
            "context": "RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2, where RNA polymerase binds in a heparin-resistant manner."
        },
        {
            "id": "641790d6690f196b5100002d_0001",
            "question": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
            "type": "factoid",
            "context": " Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age."
        },
        {
            "id": "6428da74690f196b51000052_0001",
            "question": "What is the process that generates multiple transcripts from the same gene?",
            "type": "factoid",
            "context": "Alternative splicing (Alternative splicing) generates multiple transcripts from the same gene, however, Alternative splicing contribution to proteome complexity remains elusive in plants."
        },
        {
            "id": "6428da74690f196b51000052_0002",
            "question": "What is the process that generates multiple transcripts from the same gene?",
            "type": "factoid",
            "context": "We propose that plants employ Alternative splicing not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating all Alternative splicing transcripts."
        },
        {
            "id": "6428da74690f196b51000052_0003",
            "question": "What is the process that generates multiple transcripts from the same gene?",
            "type": "factoid",
            "context": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels."
        },
        {
            "id": "6428da74690f196b51000052_0004",
            "question": "What is the process that generates multiple transcripts from the same gene?",
            "type": "factoid",
            "context": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes."
        },
        {
            "id": "64179aac690f196b51000037_0001",
            "question": "What is the life expectancy for Duchenne muscular dystrophy patients?",
            "type": "factoid",
            "context": "Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% confidence interval 25.1, 30.3)"
        },
        {
            "id": "6422ee03690f196b51000046_0001",
            "question": "What cells produce erythroferrone?",
            "type": "factoid",
            "context": ". Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis."
        },
        {
            "id": "6422ee03690f196b51000046_0002",
            "question": "What cells produce erythroferrone?",
            "type": "factoid",
            "context": "The hormone erythroferrone (erythroferrone) is produced by erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin"
        },
        {
            "id": "6422ee03690f196b51000046_0003",
            "question": "What cells produce erythroferrone?",
            "type": "factoid",
            "context": "Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice."
        },
        {
            "id": "6422ee03690f196b51000046_0004",
            "question": "What cells produce erythroferrone?",
            "type": "factoid",
            "context": "Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores."
        },
        {
            "id": "6415c0df690f196b51000010_0001",
            "question": "What does Fragment-based drug discovery stand for?",
            "type": "factoid",
            "context": "Fragment-based drug discovery (Fragment-based drug discovery) has grown and matured to a point where it is valuable to keep track of its extent and details of application. "
        },
        {
            "id": "6415b6eb690f196b5100000b_0001",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": "sensitization, behavioral changes, and low body mass index (body mass index). One possible cellular target that may mediate some of these findings is the hypocretin/orexin neurons. This neuronal system plays a role in regulating wakefulness/sleep cycles, pain perception, and appetite."
        },
        {
            "id": "6415b6eb690f196b5100000b_0002",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": " Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin and orexin. "
        },
        {
            "id": "6415b6eb690f196b5100000b_0003",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": "A low level of hypocretin-1/orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease: "
        },
        {
            "id": "6415b6eb690f196b5100000b_0004",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": "Orexins, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior and the sleep and wakefulness states."
        },
        {
            "id": "6415b6eb690f196b5100000b_0005",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": "n the present review, we firstly describe the mechanisms underlining the orexin system and their interactions with the central nervous system (central nervous system). Then, the system's involvement in goal-directed behaviors, sleep/wakefulness state regulation, feeding behavior and energy homeostasis, reward system, "
        },
        {
            "id": "6415b6eb690f196b5100000b_0006",
            "question": "What processes do orexin/hypocretin neurons regulate?",
            "type": "list",
            "context": "The effects of orexinergic peptides are diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance."
        },
        {
            "id": "6415c5d4690f196b51000014_0001",
            "question": "What was Keytruda originally approved for by the Food and Drug Administration?",
            "type": "list",
            "context": "Food and Drug Administration Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond."
        },
        {
            "id": "6415c5d4690f196b51000014_0002",
            "question": "What was Keytruda originally approved for by the Food and Drug Administration?",
            "type": "list",
            "context": "On October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (metastatic non-small cell lung cancer) whose tumors express programmed death-ligand 1 (programmed death-ligand 1) as determined by an Food and Drug Administration-approved test, as follows: (a) first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high programmed death-ligand 1 expression (tumor proportion score [tumor proportion score] \u226550%), with no epidermal growth factor receptor (epidermal growth factor receptor) or anaplastic lymphoma kinase (anaplastic lymphoma kinase) genomic tumor aberrations, and (b) treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1 (tumor proportion score \u22651%), with disease progression on or after platinum-containing chemotherapy. P"
        },
        {
            "id": "6412331b201352f04a000038_0001",
            "question": "What are Proteolysis-targeting chimeras?",
            "type": "factoid",
            "context": "Proteolysis-targeting chimeras (Proteolysis-targeting chimeras) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (ubiquitin-proteasome system)."
        },
        {
            "id": "62008022c9dfcb9c0900001b_0001",
            "question": "Which variables are included in the albumin-bilirubin grade?",
            "type": "list",
            "context": "Independent factors associated with survival were previous HCC treatment (HR 2.01, 95% confidence interval 1.23-3.27, p\u2009=\u20090.005), bi-lobar disease (HR 2.25, 95% confidence interval 1.30-3.89, p\u2009=\u20090.003), ascites (HR 1.77, 95% confidence interval 0.99-3.13, p\u2009=\u20090.05), neutrophil-to-lymphocyte ratio (HR 1.11, 95% confidence interval 1.02-1.20, p\u2009=\u20090.01), Albumin-Bilirubin (albumin-bilirubin) grade-3 (HR 2.69, 95% confidence interval 1.22-5.92, p\u2009=\u20090.01), tumor thrombus (HR 2.95, 95% confidence interval 1.65-5.24, p\u2009<\u20090.001), and disease control rate (HR 0.62, 95% confidence interval 0.39-0.96, p\u2009=\u20090.03). "
        },
        {
            "id": "62008022c9dfcb9c0900001b_0002",
            "question": "Which variables are included in the albumin-bilirubin grade?",
            "type": "list",
            "context": "We used each database to evaluate the relationship between the albumin-bilirubin grade (albumin-bilirubin) and the microbiome in patients with hepatitis C."
        },
        {
            "id": "62008022c9dfcb9c0900001b_0003",
            "question": "Which variables are included in the albumin-bilirubin grade?",
            "type": "list",
            "context": "Association between the albumin-bilirubin (albumin-bilirubin) score and severity of portopulmonary hypertension (portopulmonary hypertension): A data-mining analysis."
        },
        {
            "id": "62008022c9dfcb9c0900001b_0004",
            "question": "Which variables are included in the albumin-bilirubin grade?",
            "type": "list",
            "context": "At the diagnosis of portopulmonary hypertension, liver function was evaluated by albumin-bilirubin (albumin-bilirubin) score. "
        },
        {
            "id": "62008022c9dfcb9c0900001b_0005",
            "question": "Which variables are included in the albumin-bilirubin grade?",
            "type": "list",
            "context": "RESULTS: Fourteen, 13, and 24 patients were classified based on modified albumin-bilirubin (modified albumin-bilirubin) grade 1, 2a, and 2b, respectively. "
        },
        {
            "id": "64240f33690f196b51000049_0001",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "s Feline Infectious Peritonitis is an immune-mediated disease, treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus (feline coronavirus). Immune suppressive drugs such as prednisone or cyclophosphamide may slow disease progression but do not produce a cure. "
        },
        {
            "id": "64240f33690f196b51000049_0002",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (Feline Infectious Peritonitis) were treated with a combination of recombinant feline interferon and glucocorticoid."
        },
        {
            "id": "64240f33690f196b51000049_0003",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "YPOTHESIS: Feline interferon-omega (Feline interferon-omega) prolongs survival time and increases quality of life in cats with Feline Infectious Peritonitis.ANIMALS:"
        },
        {
            "id": "64240f33690f196b51000049_0004",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin"
        },
        {
            "id": "64240f33690f196b51000049_0005",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Propentofylline (Propentofylline) can decrease vasculitis, and therefore prolong survival time in cats with Feline Infectious Peritonitis, and increase their quality of life."
        },
        {
            "id": "64240f33690f196b51000049_0006",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Therefore, Propentofylline does not appear to be an effective treatment option in cats with a late stage of the disease Feline Infectious Peritonitis."
        },
        {
            "id": "64240f33690f196b51000049_0007",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Feline infectious peritonitis (Feline Infectious Peritonitis) is considered a fatal disease. Three cats with dry form Feline Infectious Peritonitis were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months. Further studies are necessary to assess the potential of the Polyprenyl Immunostimulant."
        },
        {
            "id": "64240f33690f196b51000049_0008",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritoniti"
        },
        {
            "id": "64240f33690f196b51000049_0009",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Feline infectious peritonitis (Feline Infectious Peritonitis) is a highly fatal disease caused by a virulent feline coronavirus in domestic and wild cats. We have previously reported the synthesis of potent coronavirus 3C-like protease (3C-like protease) inhibitors and the efficacy of a protease inhibitor, GC376, in client-owned cats with Feline Infectious Peritonitis. "
        },
        {
            "id": "64240f33690f196b51000049_0010",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro."
        },
        {
            "id": "64240f33690f196b51000049_0011",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "these data inform the potential therapeutic application of antiviral RNA interference against FIPV."
        },
        {
            "id": "64240f33690f196b51000049_0012",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "We previously reported the successful in vitro inhibition of FIPV replication by synthetic siRNA mediated RNA interference (RNA interference) in an immortalised cell line (McDonagh et al., 2011)."
        },
        {
            "id": "64240f33690f196b51000049_0013",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II."
        },
        {
            "id": "64240f33690f196b51000049_0014",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": " However, it is not clear whether HMA and other viroporin inhibitors affect replication of FIPV. "
        },
        {
            "id": "64240f33690f196b51000049_0015",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "e examined the effect of HMA and other viroporin inhibitors (DIDS [4,4'-disothiocyano-2,2'-stilbenedisulphonic acid] and amantadine) on infection by FIPV serotypes I and II. HMA treatment drastically decreased the titers of FIPV serotype I strains Black and KU-2 in a dose-dependent manner, but it only slightly decreased the titer of FIPV serotype II strain 79-1146"
        },
        {
            "id": "64240f33690f196b51000049_0016",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "In contrast, DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but it only slightly decreased the titers of FIPV serotype I strains Black and KU-2. "
        },
        {
            "id": "64240f33690f196b51000049_0017",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor."
        },
        {
            "id": "64240f33690f196b51000049_0018",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Here, we evaluated the therapeutic efficacy of our 3C-like protease inhibitor in laboratory cats with Feline Infectious Peritonitis. Experimental Feline Infectious Peritonitis is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated"
        },
        {
            "id": "64240f33690f196b51000049_0019",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis."
        },
        {
            "id": "64240f33690f196b51000049_0020",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "These results strongly suggested that the anti-fTNF-alpha antibody is effective for the treatment of Feline Infectious Peritonitis."
        },
        {
            "id": "64240f33690f196b51000049_0021",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis."
        },
        {
            "id": "64240f33690f196b51000049_0022",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological Feline Infectious Peritonitis"
        },
        {
            "id": "64240f33690f196b51000049_0023",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Mutian\u00ae Xraphconn (Mutian\u00ae Xraphconn) is a product marketed to treat cats with Feline Infectious Peritonitis but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. "
        },
        {
            "id": "64240f33690f196b51000049_0024",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Oral Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats."
        },
        {
            "id": "64240f33690f196b51000049_0025",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (Feline Infectious Peritonitis)."
        },
        {
            "id": "64240f33690f196b51000049_0026",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections"
        },
        {
            "id": "64240f33690f196b51000049_0027",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats."
        },
        {
            "id": "64240f33690f196b51000049_0028",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "In conclusion, itraconazole partly exerted a beneficial effect in a cat with Feline Infectious Peritonitis. However, further investigation of a possible role of itraconazole in Feline Infectious Peritonitis treatment is warranted."
        },
        {
            "id": "64240f33690f196b51000049_0029",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis."
        },
        {
            "id": "64240f33690f196b51000049_0030",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis"
        },
        {
            "id": "64240f33690f196b51000049_0031",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis"
        },
        {
            "id": "64240f33690f196b51000049_0032",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "S-441524 was shown to be a safe and effective treatment for Feline Infectious Peritonitis. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks."
        },
        {
            "id": "64240f33690f196b51000049_0033",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "This paper reports on the successful resolution of immunohistochemistry-confirmed effusive Feline Infectious Peritonitis in an adolescent cat in South Africa following monotherapy with remdesivir at 4.9-5.6 mg/kg daily for 80 days."
        },
        {
            "id": "64240f33690f196b51000049_0034",
            "question": "What drugs are used to treat Feline Infectious Peritonitis, Feline Infectious Peritonitis in cats?",
            "type": "list",
            "context": "uccessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir."
        },
        {
            "id": "6415c8f1690f196b51000017_0001",
            "question": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
            "type": "factoid",
            "context": "Paclitaxel, docetaxel, doxorubicin, and epirubicin have been longstanding,\u00a0Food and Drug Administration (Food and Drug Administration)-approved therapies against TNBC."
        },
        {
            "id": "63eeec79f36125a426000006_0001",
            "question": "Talquetamab was developed for treatment of which disease?",
            "type": "factoid",
            "context": "Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma."
        },
        {
            "id": "63eeec79f36125a426000006_0002",
            "question": "Talquetamab was developed for treatment of which disease?",
            "type": "factoid",
            "context": "The bispecific antibodies teclistamab (BCMA\u00d7CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM. "
        },
        {
            "id": "6422e2f1690f196b51000043_0001",
            "question": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
            "type": "factoid",
            "context": "Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent Food and Drug Administration approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively."
        },
        {
            "id": "6422e2f1690f196b51000043_0002",
            "question": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
            "type": "factoid",
            "context": "the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, N-acetylgalactosamine,"
        },
        {
            "id": "6422e2f1690f196b51000043_0003",
            "question": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
            "type": "factoid",
            "context": "GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (asialoglycoprotein receptor) mediated uptake in the hepatocytes"
        },
        {
            "id": "6422e2f1690f196b51000043_0004",
            "question": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
            "type": "factoid",
            "context": "hree such products (givosiran, lumasiran and inclisiran) are liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand. Upon subcutaneous administration,"
        },
        {
            "id": "6422e2f1690f196b51000043_0005",
            "question": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
            "type": "factoid",
            "context": "Beyond that, we show that GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin in murine primary hepatocytes and in\u00a0vivo in mice."
        },
        {
            "id": "6432fb1957b1c7a31500001e_0001",
            "question": "What clinical applications is Zanubrutinib approved for in the United States?",
            "type": "list",
            "context": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. "
        },
        {
            "id": "6432fb1957b1c7a31500001e_0002",
            "question": "What clinical applications is Zanubrutinib approved for in the United States?",
            "type": "list",
            "context": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy."
        },
        {
            "id": "6413712a201352f04a00003e_0001",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Lower grade gliomas (Lower grade gliomas) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have a favorable outcome. "
        },
        {
            "id": "6413712a201352f04a00003e_0002",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase (isocitrate dehydrogenase) genes were common in lower grade glioma (Lower grade glioma: grade2-3), and when combined with 1p/19q status,"
        },
        {
            "id": "6413712a201352f04a00003e_0003",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including isocitrate dehydrogenase mutations, 1p19q co-deletion status and MGMT promoter methylation have been proven to be prognostic and predictive to response to treatment in gliomas. I"
        },
        {
            "id": "6413712a201352f04a00003e_0004",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted: 37;"
        },
        {
            "id": "6413712a201352f04a00003e_0005",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma."
        },
        {
            "id": "6413712a201352f04a00003e_0006",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "The presence of chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma, using the 2016 World Health Organization (World Health Organization) Classification of Tumours of the Central Nervous System."
        },
        {
            "id": "6413712a201352f04a00003e_0007",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Descriptions in the literature of astrocytomas, primarily glioblastomas, demonstrating partial losses on one or the other chromosome have been described."
        },
        {
            "id": "6413712a201352f04a00003e_0008",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Oligodendroglial tumours (Oligodendroglial tumours) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the isocitrate dehydrogenase mutation and 1p/19q co-deletion."
        },
        {
            "id": "6413712a201352f04a00003e_0009",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": " three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (oligodendrocyte precursor cell) and neuronal lineage."
        },
        {
            "id": "6413712a201352f04a00003e_0010",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/isocitrate dehydrogenase mutant, intact 1p/19q/isocitrate dehydrogenase mutant and isocitrate dehydrogenase wild type."
        },
        {
            "id": "6413712a201352f04a00003e_0011",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "Co-deletion of 1p/19q is a hallmark of oligodendroglioma and predicts better survival."
        },
        {
            "id": "6413712a201352f04a00003e_0012",
            "question": "The 1p19q co-deletion is associated with what types of tumors?",
            "type": "list",
            "context": "The second is that examinations for isocitrate dehydrogenase mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma patients."
        },
        {
            "id": "6429ad3857b1c7a315000003_0001",
            "question": "The X-inactive specific transcript (X-inactive specific transcript) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does X-inactive specific transcript encode?",
            "type": "factoid",
            "context": "X-inactive specific transcript encodes a long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of X-inactive specific transcript RNA."
        },
        {
            "id": "6429ad3857b1c7a315000003_0002",
            "question": "The X-inactive specific transcript (X-inactive specific transcript) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does X-inactive specific transcript encode?",
            "type": "factoid",
            "context": "XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X chromosome and is involved in the X-inactivation process."
        },
        {
            "id": "6429ad3857b1c7a315000003_0003",
            "question": "The X-inactive specific transcript (X-inactive specific transcript) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does X-inactive specific transcript encode?",
            "type": "factoid",
            "context": "XIST encodes a functional RNA that is expressed exclusively from the inactive X in female mammals and is required for the silencing of most of the genes on the chromosome. XIST transcripts remain in the nucleus, and their specific localization to the inactive X is important for silencing; however, it is not known how these transcripts localize to the inactive X chromosome."
        },
        {
            "id": "6429ad3857b1c7a315000003_0004",
            "question": "The X-inactive specific transcript (X-inactive specific transcript) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does X-inactive specific transcript encode?",
            "type": "factoid",
            "context": "Dosage compensation in mammals is achieved by the transcriptional inactivation of one X chromosome in female cells."
        },
        {
            "id": "6429ad3857b1c7a315000003_0005",
            "question": "The X-inactive specific transcript (X-inactive specific transcript) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does X-inactive specific transcript encode?",
            "type": "factoid",
            "context": "Silencing on the inactive X chromosome coincides with the acquisition of a multitude of chromatin modifications, resulting in the formation of extraordinarily stable facultative heterochromatin that is faithfully propagated through subsequent cell divisions. The integration of all these processes requires a region of the X chromosome known as the X-inactivation center, which contains the X-inactive specific transcript gene and its cis-regulatory elements. X-inactive specific transcript encodes an RNA molecule that plays critical roles in the choice of which X chromosome remains active, and in the initial spread and establishment of silencing on the inactive X chromosome."
        }
    ]
}